These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31765938)
1. Role of cancer immunology in chronic myelogenous leukemia. Ureshino H; Shindo T; Kimura S Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938 [TBL] [Abstract][Full Text] [Related]
2. Treatment-free remission and immunity in chronic myeloid leukemia. Ureshino H Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270 [TBL] [Abstract][Full Text] [Related]
3. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG Front Immunol; 2018; 9():3152. PubMed ID: 30705677 [TBL] [Abstract][Full Text] [Related]
4. Allelic polymorphisms of Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973 [TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia and NK cell immunity]. Ureshino H; Shindo T; Tanaka H; Kimura S Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170 [TBL] [Abstract][Full Text] [Related]
6. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Hsieh YC; Kirschner K; Copland M Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387 [TBL] [Abstract][Full Text] [Related]
7. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M Front Immunol; 2018; 9():2587. PubMed ID: 30487792 [TBL] [Abstract][Full Text] [Related]
8. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission. Hughes A; Yong ASM Front Immunol; 2017; 8():469. PubMed ID: 28484463 [TBL] [Abstract][Full Text] [Related]
9. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055 [TBL] [Abstract][Full Text] [Related]
10. [Immunological evaluation for CML and its possibility for an immunotherapy]. Fujii S Nihon Rinsho Meneki Gakkai Kaishi; 2009 Aug; 32(4):231-41. PubMed ID: 19721343 [TBL] [Abstract][Full Text] [Related]
11. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors. Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P Front Immunol; 2019; 10():2493. PubMed ID: 31695700 [TBL] [Abstract][Full Text] [Related]
13. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. Kim PS; Lee PP; Levy D PLoS Comput Biol; 2008 Jun; 4(6):e1000095. PubMed ID: 18566683 [TBL] [Abstract][Full Text] [Related]
14. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia. Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420 [TBL] [Abstract][Full Text] [Related]
15. γδ T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia. Molina-Aguilar R; Montiel-Cervantes LA; Anguiano-Peñaloza SV; Lezama R; Vela-Ojeda J; Reyes-Maldonado E Arch Med Res; 2020 Apr; 51(3):194-203. PubMed ID: 32113783 [TBL] [Abstract][Full Text] [Related]